| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Dexecadotril | Phase 3 Clinical | Bioprojet Pharma | Gastrointestinal Diseases | Details | |
| Sacubitril/Valsartan (Chong Kun Dang Pharmaceutical) | CKD-202A | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Essential Hypertension | Details |
| QR-12000 | QR-12000 | Phase 3 Clinical | Wuhan Createrna Science and Technology Co Ltd | Essential Hypertension; Hypertension | Details |
| Debio-0827 | PL-37; Debio-0827 | Phase 2 Clinical | Pharmaleads | Pain | Details |
| Sacubitril | AHU-377 | Phase 2 Clinical | Novartis Pharma Ag | Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Diabetes Mellitus; Essential Hypertension; Heart Failure; Hypertension; Insulin Resistance; Metabolic Diseases | Details |
| Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Sacubitril Valsartan Sodium Extended-Relesae Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Heart Failure | Details | |
| Sacubitril/Allisartan Isoproxil/Amlodipine Besylate | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Essential Hypertension | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacubitril/Allisartan Isoproxil | AHU-377/EXP3174; S-086 | Approved | Shenzhen Salubris Pharmaceuticals Co Ltd | 信超妥 | Mainland China | Essential Hypertension | Shenzhen Salubris Pharmaceuticals Co Ltd | 2025-05-20 | Essential Hypertension; Heart Failure; Hypertension | Details |
| Sacubitril/Valsartan Sodium Hydrate | LCZ-696; LCZ-696A | Approved | Novartis Pharma Ag | ENTRESTO SPRINKLE, Enresuto, Enrest, Entresto, Neparvis, 诺欣妥, 科畅欣 | United States | Heart Failure | Novartis Pharmaceuticals Corp | 2015-07-07 | Breast Neoplasms; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Erectile Dysfunction; Essential Hypertension; Heart Defects, Congenital; Heart Diseases; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Hepatic Insufficiency; Hypertension; Lymphoma; Myocardial Infarction; Obesity; Peripheral Arterial Disease; Postmyocardial Infarction Syndrome; Renal Insufficiency; Renal Insufficiency, Chronic; Ventricular Dysfunction, Left | Details |
| Racecadotril | Tiorfan; Hidrasec | Approved | Bioprojet Pharma | France | Diarrhea | Bioprojet Pharma | 1993-03-23 | Diarrhea; Diarrhea, Infantile; Sepsis | Details |